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INTRODUCTION
As we come to the close of the second millenium, it is
i n t e resting to note that almost everything we know about
the transplantation of tissues and organs has come about
in the 20th century. Alexis Carrel received the Nobel
Prize in medicine in 1912 for his work on vascular suture s
and the transplantation of blood vessels and organs. He
and others showed that an allogeneic graft could function
for a time but then would fail. The antigenic basis of
tumor transplants was established based on experiments in
m i c e[ 1 ] and led to the recognition of the H2 transplanta-
tion antigen system [2]. Medawar clearly established the
immunologic  basis for graft reject ion and described
neonatal tolerance in mice [3]. Thus, at the end of Wo r l d
War II, the stage was set for the development of hemato-
poietic cell transplantation.
This brief account of historical markers is intended to
highlight those publications that had a direct bearing on the
clinical application of hematopoietic cell transplantation.
T h ree excellent monographs provide detailed inform a t i o n
about the development of transplantation biology [4–6].
1949–1951: THE HUMORAL HYPOTHESIS 
During this time, because of the possibility of atomic
w a rf a re and the newly available radioactive isotopes, there
was a great deal of interest in the biological effects of irradi-
ation. It was recognized that the bone marrow was the most
sensitive organ in the body and that marrow failure was the
cause of death at low lethal radiation exposures. In 1949,
Jacobson et al. found that mice could survive an otherw i s e
lethal irradiation exposure if the spleen were protected by a
lead foil [7]. In 1951, Lorenz et al. described a similar pro-
tective effect of an infusion of spleen or marrow cells [8]. It
was logical to think that the marrow recovery was the conse-
quence of humoral or hormonal factors that stimulated the
marrow regrowth and, thus, allowed the mice to survive.
1954–1956: THE CELLULAR HYPOTHESIS 
In 1954, Barnes and Loutit noted that the re c o v e ry
b rought about by spleen or marrow cell infusion might be due
to living cells and that the re p o rted experiments did not
exclude the cellular hypothesis [9]. In 1955, Main and Pre h n
described studies of lethally irradiated mice protected by a mar-
row infusion and given subsequent skin grafts from the marro w
donor [10]. Even across major histocompatibility barr i e r s ,
donor skin grafts were not rejected, a proof of tolerance that
could be explained only by the transfer of living cells. In 1956,
F o rd et al. showed that the marrow of such mice displayed the
cytogenetic characteristics of the marrow donor [11].
1956–1959: RECOGNITION OF THE POTENTIAL OF
MARROW GRAFTING IN THE TREATMENT OF HUMAN
DISEASE
In 1956, Barnes et al. described the treatment of murine
leukemia by supralethal irradiation and marrow grafting [12].
They pointed out the potential application of marrow graft-
ing to human patients. Attempts to treat human patients by
supralethal irradiation and marrow grafting were re p o rted by
Thomas et al. in 1957 [13]. In 1958, Kurnick et al. d e s c r i b e d
the use of the patients’ own marrow to facilitate marro w
re c o v e ry of patients with solid tumors treated intensively with
c h e m o - i rradiation [14]. In 1959, Thomas et al. re p o rted two
patients with advanced leukemia who were treated with
supralethal irradiation and marrow from their identical twins.
Although their leukemia came back in a few months, they
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w e re the first patients deliberately given supralethal irr a d i a-
tion, and their prompt hematological re c o v e ry supported the
principles underlying this new treatment strategy [15].
1956–1959: ADVANCES IN MARROW GRAFTING
TECHNOLOGY THROUGH ANIMAL STUDIES 
Experiments in inbred mice defined the immunology of
allogeneic grafting. It was shown in mice that intravenous
infusion was the optimal route for administration of marro w
stem cells [16]. Bellingham and Brent found that allogeneic
cells in the marrow graft could mount an immune re a c t i o n
against the tissue of the host, resulting in a wasting syndro m e
now known as graft-vs.-host disease (GVHD) [17]. Uphoff
re p o rted that genetic factors controlled the immune re a c-
tions of donor cells against the host [18] and that methotre x-
ate could ameliorate the graft-vs.-host reaction [19]. 
Following the Main and Prehn re p o rt described above
and its confirmation by other re s e a rchers, there was a gre a t
deal of interest in the possibility that a marrow graft followed
by an organ graft might be a general method for allogeneic
transplantation in mammalian species. In 1959, Mannick
et a l . described a dog given lethal irradiation and a marro w
graft, followed by a kidney transplant, from an unrelated dog
[20]. The treated dog died of pneumonia 73 days after irr a d i-
ation and 49 days after the kidney graft, with a cellular mar-
row and no sign of rejection of the kidney. This animal illus-
trated proof that marrow graft followed by organ graft could
be successful, but, unfort u n a t e l y, demonstrated the hazard s
of allogeneic marrow grafting. This approach to allogeneic
o rgan transplantation was abandoned because of similar dis-
asters in human patients and also because immunosuppre s-
sive drugs were beginning to be introduced at that time.
1960–1967: PESSIMISM ABOUT ALLOGENEIC MARROW
GRAFTING IN HUMAN PATIENTS BUT PROGRESS IN
ANIMAL MODELS OF ALLOGENEIC MARROW GRAFTING 
B o rtin collected data about approximately 200 human
allogeneic marrow grafts carried out in the 1950s and
1960s and concluded that none had been successful [21].
Mathé et al. achieved the first allogeneic marrow graft in a
patient with leukemia, but the patient died with many
p roblems that probably were due to the complications of
c h ronic GVHD [22]. Continued success with transplanta-
tion between identical twins demonstrated the feasibility of
m a rrow grafting between histocompatible donors and
re c i p i e n t s .
Dogs are an outbred species suitable for clinical pro c e-
d u res used for human patients, and family groups of them
a re readily available. It was found that dogs could surv i v e
2 to 4 times the lethal exposure to irradiation if given an
intravenous infusion of their own marrow cells that had
been set aside or cry o p re s e rved before the irr a d i a t i o n
[23,24]. Studies in dogs demonstrated the spectrum of
results following allogeneic marrow grafting, including
f a i l u re of engraftment, graft rejection, engraftment fol-
lowed by GVHD, and stable engraftment without GVHD
[25]. Hematopoiet ic cell s for engraftment could be
obtained from the peripheral blood in dogs as well as in
mice [26,27].
Dausset et al. and van Rood et al. had described human
leukocyte antigen (HLA) groups [28,29], and it  was
thought that these antigens might be important in trans-
plantation. Studies of skin graft survival in human volun-
teers suggested that the human leukocyte antigens were
histocompatibility antigens, but the graft survivals were
d i fficult to interpret and the technique carried the risk of
transmission of disease to and sensitization of the re c i p i-
ent [30].
Studies of the dog leukocyte antigen system pro v e d
that dog leukocyte antigens (DLA) were crucial in deter-
mining the outcome of an allogeneic marrow graft [31].
Dogs given irradiation and marrow from a DLA-mism a t c h e d
l i t t e rmate died of graft rejection or GVHD. Most re c i p i-
ents of DLA-matched marro w, especially those given some
postgrafting methotrexate to suppress the GVH re a c t i o n ,
became long-term healthy survivors [32–34] (Fig. 1).
These observations encouraged further trials of marro w
grafting between matched human siblings.
Figure 1. Outcome in dogs after transplantation following irradiation
Survival of dogs given 1000 rad total body irradiation and marrow from littermates matched and mismatched for dog leukocyte antigens. Some recipients of
matched marrow were given a short course of intermittent methotrexate after grafting to suppress the GVH reaction (adapted from [31–33]).
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1968–1975: THE BEGINNING OF THE MODERN ERA OF
HUMAN MARROW TRANSPLANTATION 
Effective supportive care of the patient without marrow
function had been developed by 1968, including blood com-
ponent transfusion technology and improved antibiotics.
I n c reasing knowledge of HLA systems made it possible to
select compatible family members as marrow donors. In
1968 and 1969, three infants with immune deficiency dis-
eases received successful transplants from HLA-matched
siblings [35–37]. Because of their disease, these patients
re q u i red neither immunosuppression to prevent re j e c t i o n
and GVHD nor cytotoxic agents to eliminate malignancy.
More than 25 years later, these three patients are well and
are leading normal lives. 
Successful marrow grafts from matched siblings pro v e d
to be much more difficult to achieve for older children and
adults with advanced leukemia or aplastic anemia. In 1969,
the Seattle team treated a patient with the blastic phase of
c h ronic myeloid leukemia by total body irradiation and mar-
row transplantation from a matched sibling. The transplan-
tation was successful, but the patient died of cytomegaloviru s
pneumonia, an early example of the problem of opport u n i s-
tic infections in the postgrafting period [38].
In 1972, the Seattle team re p o rted successful transplan-
tations for patients with severe aplastic anemia [39]. In 1975,
a review article by members of the team described the state
of knowledge of marrow transplantation at that time [40].
The article described the results in 37 patients with severe
aplastic anemia and 73 with leukemia in the terminal phase
of their disease who received transplants after failure of con-
ventional treatment. Notable results were successful engraft-
ment of some patients with aplastic anemia, and engraftment
and survival in remission of a few patients with leukemia.
1976–1986: WIDENING APPLICATION OF ALLOGENEIC
MARROW GRAFTING FOR HUMAN PATIENTS
In 1976, the Seattle team reported the development of a
plateau on a semilog plot of a Kaplan-Meier disease-fre e
survival curve, suggesting that some patients with advanced
leukemia were being cured by chemo-irradiation and mar-
row grafting [4l]. In 1977, they reported the long-term sur-
vival of 13 of 100 patients who received transplants for
advanced leukemia [42].
Once it was shown that some patients in the end stages
of leukemia could be cured, it became possible to consider
transplantations earlier in the course of the disease. In 1979,
two reports of transplantation for acute myeloid leukemia in
first remission showed greatly improved results [43,44].
C h ronic myeloid leukemia (CML) had not been cure d
by chemotherapy, but in 1979, Fefer et al. described the dis-
appearance of the Ph chromosome in four patients tre a t e d
with chemotherapy, irradiation, and an identical twin mar-
row transplant [45]. Pre l i m i n a ry re p o rts had described tre a t-
ment of CML in chronic phase by chemo-irradiation and
allogeneic marrow transplantation from a matched sibling
[46,47]. In 1986, two studies of large numbers of patients
with CML re p o rted that a majority could be cured by
c h e m o - i rradiation and a marrow graft [48,49]. Figure 2
shows the clinical results of 389 patients with CML who
received marrow grafts from histocompatible related donors. 
The first cures of Thalassemia major and of sickle cell
disease were also re p o rted during this period [50,51]. Figure 3
illustrates the outcome of transplantation for 34 patients
with sickle cell anemia. Better prevention and control of
GVHD came from removal of T cells from the marro w
innoculum [52,53] or by a combination of a short course of
methotrexate combined with cyclosporine [54,55].
Figure 2. Patient outcome after transplantation for CML
Kaplan-Meier estimates for survival, event-free survival, and cumulative incidence of relapse through 1996 for 389 patients in Seattle with CML who received
transplants from HLA-identical related donors during the chronic phase after treatment with either cyclophosphamide with total body irradiation or busulfan with
cyclophosphamide (reproduced by permission from Thomas ED and Cliff RA: Allogeneic transplantation for chronic myeloid leukemia. In: ED Thomas, KG
Blume, SJ Forman [eds] Hematopoietic Cell Transplantation. 2nd ed. Boston: Blackwell Science, 811, 1999).
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1986–PRESENT: HEMATOPOIETIC CELL
TRANSPLANTATION AS STANDARD THERAPY 
With hundreds of marrow transplant teams re p o rt i n g
data, it is not possible to cite all the important publications in
the space available. Among the most notable are the following:
• The development of the preparative regimen of cyclophos-
phamide and busulfan that avoids the use of irr a d i a t i o n
for some diseases [56].
• The introduction of ganciclovir for the control of
cytomegalovirus infections [57,58] (reviewed in [59]).
• The use of donor lymphocyte infusions for eradication of
re c u rrent leukemia or lymphoproliferative disease [60–62].
• The use of hematopoietic stem cells from peripheral
blood or cord blood, which has changed the term i n o l o g y
f rom marrow transplantation to hematopoietic cell trans-
plantation [63–65] .
• The advances in immunogenetics of HLA, especially typ-
ing by molecular techniques (reviewed in [66]).
• The creation of large panels of tissue-typed volunteer
donors that has made possible transplantations fro m
donors who are not family members [67,68]. Donor reg-
istries have been established in many countries to facili-
tate international cooperation in locating matched mar-
row donors (reviewed in [69]).
• Hematopoietic cell transplantation using nonmyeloabla-
tive techniques to avoid re g i m e n - related toxicity and
death [70] (reviewed in [7l]). These techniques suggest
the feasibility of using hematopoietic cell transplantation
as a treatment for autoimmune diseases and preparation
for solid organ grafts.
• Successful crossing of the HLA barr i e r, allowing allo-
geneic hematopoietic cell transplantation from haplotype-
matched related donors [72–74]. The report by Guinan
et a l . opens a new approach to the transplantation of his-
toincompatible marrow allografts, using cells made aner-
gic by elimination of costimulatory signals [75].
CONCLUSION
During the second half of the 20th century, several
generations of investigators from many countries have
contributed a wealth of scientific information based on
experimental and clinical re s e a rch. These eff o rts have
changed the role of hematopoietic cell transplantation
f rom a desperate therapeutic maneuver to a curative tre a t-
ment modality for thousands of patients, especially when it
is used for patients in the early stages of their disease. The
number of diseases for which hematopoietic cell transplan-
tation can be applied is also increasing rapidly. During the
next decades, we are likely to witness a continued gain of
new re s e a rch information, leading to novel and impro v e d
concepts that may further extend the application of this
f o rm of tre a t m e n t .
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